Kura Oncology Reports Q1 KOMZIFTI Launch Drives Revenue Growth, Extends Cash Runway
Kura Oncology reported first-quarter 2026 net product revenue driven by its February launch of KOMZIFTI, with prescription uptake in resistant hematologic cancers. The company ended March with sufficient cash to fund operations into 2027 and advanced its farnesyltransferase inhibitor and other candidates into new clinical studies.
1. Q1 Revenue and KOMZIFTI Launch
Kura Oncology posted first-quarter 2026 results, reporting significant net product revenue from the U.S. launch of KOMZIFTI in February. Early physician adoption in resistant hematologic malignancies drove prescription volume beyond management expectations.
2. Strong Balance Sheet and Runway
The company closed March with approximately $300 million in cash and marketable securities, providing funding into mid-2027. This robust balance sheet reduces the need for near-term financing while supporting ongoing development.
3. Pipeline Advancement
During Q1, Kura initiated a Phase II study of its farnesyltransferase inhibitor tipifarnib in head and neck cancer and moved two preclinical programs toward clinical proof-of-concept. These advancements underscore the company’s commitment to broadening its oncology portfolio.
4. Strategic Outlook
Management reaffirmed full-year development milestones and plans to pursue label expansions for KOMZIFTI in additional tumor types later this year. The company also highlighted plans for interim data releases from its newer assets in the second half of 2026.